Fox Business - The Power to Prosper
Search Site

Wednesday, April 7, 2010 as of 11:14 AM ET

Orexigen Therapeutics

More Headlines »« Less Headlines

Related Topics

  1. Food And Drug Administration
  2. Miles White
  3. Pharmaceuticals
  4. John Mackey
  5. Mark Parker
  6. Robert Dudley
Get updates on Orexigen Therapeutics
Health Care Sector Wrap

During trading today, the Health Care sector (XLV) showed little change while the S&P 500 fell 0.

3%.The ETF, as a proxy for the sector, tracked closer to the overall market today than over the past month. Entering today's trading, XLV was up 0.2% over the last thirty trading days while the S&P 500 climbed -2.3%.IPC The Hospitalist Company (NASDAQ:IPCM) declined 2.2% to close at $36.83, moving below its 50-day moving average of $37.00 and 200-day moving average of $38.01. Orexigen Therapeutics (NASDAQ:OREX) rose 19.1% to close at $3.99, crossing its 50-day moving average of $3.88.ABIOMED (NASDAQ:SNN) fell 3.4% to close at $23.19, moving closer to its 50-day moving average of $22.59. Also, the stock moved closer to its 200-day moving average of $48.12.OraSure Technologies (NASDAQ:OSUR) was one of the sector's big losers, as its price dropped 11.8% (-$1.32) to close at $9.85. 1.7 million shares of the stock moved. The stock traded in a range of $9.55 to $11.17. The stock is down over the ...

Read More ›

  1. Orexigen Obesity Drug Gains Traction Toward FDA Approval

    Orexigen Therapeutics (NASDAQ:OREX) surged more than 110% to a two-year high Wednesday after announcing federal support for its weight loss drug Contrave, moving the...

  2. The Skinny on Diet Pills

    FOXNewshealth.com Managing Editor Dr. Manny Alvarez on the new diet pill Contrave, backed by the FDA.

  3. Orexigen and Takeda Partner to Commercialize Obesity Treatment

    Orexigen Therapeutics (NASDAQ:OREX) ticked up more than 24% early Thursday on news that it has entered into a partnership with Japan’s Takeda Pharmaceutical to comme...

  4. Back-to-School Hits the Road

    We break down what consumers are expecting from back-to-school sales, and what will keep you going the rest of the summer.

  1. Arena News Boosts Orexigen , Vivus Shares

    Shares of diet-drug developer Orexigen Therapeutics shot up 20% to $4.03 Friday in the wake of news that an advisory panel of the U.S. Food and Drug Administration h...

  2. Arena Rockets On FDA Nod

    Arena Pharmaceuticals shares rocketed 75% to $6.42 early Friday, the day after an advisory panel of the U.S. Food and Drug Administration voted to recommend agency a...

  3. FDA Weighs Heart Trials for Obesity Drugs

    U.S. health regulators are asking for advice on whether, and when, heart safety studies should be required for new obesity drugs, possibly adding a new hurdle on the...

  4. Vivus Rockets 99% On FDA Nod

    Shares of Vivus Inc. rocketed 99% to $20.95 early Thursday, the day after an advisory panel of the U.S. Food and Drug Administration voted to recommend the agency ap...

  5. FDA Official Sees Drug Approvals Rising

    The Food and Drug Administration is seeing a rising number of new drugs ready for approval and expects a gradual increase in medicines that reach the market, a top a...

  6. Blue Chips Blow Past 12000 in Bullish February Debut

    FOX Business: The Power to ProsperWall Street flipped the calendar to February with bullish enthusiasm on Tuesday as the Dow surged beyond 12000 and the S&P 500 conq...

  7. Orexigen Shares Jump Ahead Of FDA Decision

    BOSTON -- Shares of Orexigen Therapeutics jumped 10% Monday morning. The U.S. Food and Drug Administration is expected to issue a decision by the end of Monday on wh...

Freebase CC-BY
Source: Orexigen Therapeutics on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL